Collin Hauskins

home / authors / collin-hauskins

Collin Hauskins began his career at Zymogenetics and Novo Nordisk working on a range of immuno‑oncology programmes. Collin has been at Juno Therapeutics, a Bristol Myers Squibb company, since 2014 and currently leads the Raw Materials Group. His team is responsible for developing analytical methods for raw materials used in the manufacture of CAR-T cell therapies.

Articles